Jason Heil, MD
Neurology · Cincinnati, OHNPI 1790996007
Payments from drug & device makers
Across 129 payments — averaging $24.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$734
- AbbVie$715
- SK Life Science, Inc.$348
- UCB, Inc.$341
- Boston Scientific$145
- Argenx US, Inc.$143
- plus $684 from 18 others
What the payments were for
- Food & beverage$3,08099%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 24 | $734 |
| AbbVie | 52 | $715 |
| SK Life Science, Inc. | 4 | $348 |
| UCB, Inc. | 10 | $341 |
| Boston Scientific | 1 | $145 |
| Argenx US, Inc. | 5 | $143 |
| Acadia Pharmaceuticals Inc | 4 | $104 |
| Biogen | 4 | $74 |
| Neurocrine Biosciences, Inc. | 2 | $70 |
| Amneal Pharmaceuticals LLC | 4 | $62 |
| Johnson & Johnson(2 entities) | 3 | $55 |
| TG Therapeutics, Inc. | 2 | $39 |
| Eisai Inc. | 1 | $32 |
| Lilly USA, LLC | 2 | $30 |
| Amgen | 2 | $29 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Jazz Pharmaceuticals Inc. | 1 | $26 |
| Lundbeck LLC | 1 | $26 |
| Genentech USA, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Bioventus LLC | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Pfizer | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XCOPRI$341
- WATCHMAN Access System$145
- SOLIRIS$118
How this compares
$3,110 in reported general payments places this provider in the 55th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Vyvgart HytruloEfgartigimod-Hyaluronidas-Qvfc | 15 | $916,456 |
| SolirisEculizumab | 13 | $710,047 |
| UltomirisRavulizumab-Cwvz | 14 | $563,043 |
| NuplazidPimavanserin Tartrate | 12 | $62,847 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 11 | $10,443 |
| Pyridostigmine Bromide | 42 | $4,300 |
| Mycophenolate Mofetil | 16 | $2,402 |
| Azathioprine | 38 | $2,078 |
| Carbamazepine ErCarbamazepine | 17 | $2,008 |
| Memantine Hcl | 79 | $1,812 |
| Carbamazepine | 15 | $1,770 |
| Lacosamide | 13 | $1,515 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 42 | $1,157 |
| Levetiracetam | 30 | $747 |
| Oxcarbazepine | 12 | $692 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSoliris, Ultomiris | $734 | $1,273,09027 claims |
| Argenx US, Inc.Vyvgart Hytrulo | $143 | $916,45615 claims |
| Acadia Pharmaceuticals IncNuplazid | $104 | $62,84712 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil | $62 | $6,70258 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 702 neurology providers in Ohio.
Other neurology in Cincinnati
- Aram ZabetiCincinnati$5.3M
- Hani KushlafCincinnati$1.9M
- Alberto EspayCincinnati$785K
- Brandon ForemanCincinnati$677K
- Andrew DukerCincinnati$620K
- Michelle BowmanCincinnati$419K
- Joel VandersluisDayton$12.3M
- Jerry MendellColumbus$11.5M
- Lawrence GoldstickDayton$6.9M
- Douglas ScharreColumbus$6.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.